Myoepithelial Carcinoma.
Adenoma, Pleomorphic
/ diagnosis
Diagnosis, Differential
Epithelial Cells
/ pathology
Humans
Immunohistochemistry
Myoepithelioma
/ diagnosis
Necrosis
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Recurrence, Local
Neoplasms, Multiple Primary
/ diagnosis
Prognosis
Salivary Gland Neoplasms
/ diagnosis
Carcinoma ex pleomorphic adenoma
Myoepithelial carcinoma
PLAG1
Pleomorphic adenoma
Journal
Surgical pathology clinics
ISSN: 1875-9157
Titre abrégé: Surg Pathol Clin
Pays: United States
ID NLM: 101491209
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
15
10
2021
Statut:
ppublish
Résumé
Myoepithelial carcinoma (MECA) may overlap histologically with other salivary gland neoplasms, especially pleomorphic adenoma. MECA is characterized by cellular, uniform growth of myoepithelial cells and multinodular expansile invasive pattern with zonal cellular distribution. It may arise de novo or in association with pleomorphic adenoma (myoepithelial carcinoma ex pleomorphic adenoma). By immunohistochemistry, MECA is positive for cytokeratins and at least one of the myoepithelial markers, including S100. PLAG1 fusion is the most common genetic alteration. Carcinoma ex pleomorphic adenoma and necrosis correlate with worse clinical outcome in MECA, and necrosis can be used to stratify MECA as high grade.
Identifiants
pubmed: 33526224
pii: S1875-9181(20)30070-2
doi: 10.1016/j.path.2020.09.008
pmc: PMC8522910
mid: NIHMS1743825
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-73Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose. Research reported in this publication was supported in part by the Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute under award number P30CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Références
Mod Pathol. 2005 Aug;18(8):1048-55
pubmed: 15920557
Hum Pathol. 2017 Sep;67:37-44
pubmed: 28739497
Head Neck Pathol. 2012 Sep;6(3):328-35
pubmed: 22485045
Hum Pathol. 2010 Jul;41(7):927-34
pubmed: 20338616
Arch Otolaryngol Head Neck Surg. 2010 Jul;136(7):702-12
pubmed: 20644067
Hum Pathol. 2015 Jan;46(1):26-33
pubmed: 25439740
Am J Surg Pathol. 2019 May;43(5):601-609
pubmed: 30789358
J Formos Med Assoc. 1997 Mar;96(3):209-12
pubmed: 9080761
Am J Ophthalmol. 2013 Dec;156(6):1147-1158.e1
pubmed: 23972314
Am J Surg Pathol. 2015 Mar;39(3):338-48
pubmed: 25581728
Histopathology. 1998 Nov;33(5):485
pubmed: 9839176
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Jul;110(1):85-93
pubmed: 20488733
Cancer. 1998 Oct 1;83(7):1292-9
pubmed: 9762928
Am J Surg Pathol. 2000 Jun;24(6):761-74
pubmed: 10843278
Histopathology. 1996 Apr;28(4):309-15
pubmed: 8732339
Histopathology. 2018 Jan;72(2):285-293
pubmed: 28796899
Am J Surg Pathol. 2015 Jul;39(7):931-8
pubmed: 25970687
Nat Commun. 2017 Oct 30;8(1):1197
pubmed: 29084941